Biopharmaceutical company Amgen won a major victory in case involving the infringement of two patents held by the company.
A federal judge has upheld an injunction that prevents Sanofi and Regeneron, the defendants in the case, from using the patents help by Amgen for the use of Repatha. The injunction prevents the manufacture, use or sale of the drug by Sanofi and Regeneron. The judge’s decision follows a March 2016 jury verdict that ruled in Amgen’s favor.
“We are pleased with today’s decision that recognizes Amgen is entitled to an injunction against further infringement of our patent rights,” Amgen CEO Robert Bradway said. “Sanofi and Regeneron admitted that they had infringed our patents and the jury upheld our patents as valid. Protecting intellectual property is essential to our industry as it reinforces the incentives for the large and frisky investments we make in innovation to bring forward new medicines to treat serious diseases.”
Repatha is used in the treatment of patients who suffer from cardiovascular diseases and helps maintain low cholesterol levels.
Amegen secures major victory in patent infringement case
Alerts Sign-up